Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Norel AD is an FDA-approved, over-the-counter (OTC) combination drug manufactured by U.S. Pharmaceutical Corporation. It is formulated as a multilayer oral tablet containing acetaminophen (325 mg), chlorpheniramine maleate (4 mg), and phenylephrine hydrochloride (10 mg). The drug is indicated for the relief of symptoms associated with the common cold, influenza, allergies, and sinusitis, including nasal congestion, runny nose, sneezing, sinus headache, fever, and minor aches and pains. Mechanistically, it combines the analgesic and antipyretic effects of acetaminophen, the antihistaminic properties of chlorpheniramine (a first-generation H1 receptor antagonist), and the decongestant action of phenylephrine (an alpha-1 adrenergic receptor agonist).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acetaminophen + chlorpheniramine + phenylephrine.